CLEVELAND, Ohio — Lubrizol announces that an Apisolex™ polymer excipient-enabled drug formulation is in Phase 1 clinical trials.
Introduced to the market in 2022, Apisolex polymer excipient is a polyamino acid-based polymer that enhances the solubility of BCS Class II and IV active pharmaceutical ingredients (API). Apisolex polymer excipient is manufactured following Good Manufacturing Practices (GMP) guidelines and can be used in dosage forms for various routes of administration, including parenteral.
The use of Apisolex polymer excipient has been proven to increase the solubility of certain APIs by as much as 50,000-fold. Apisolex polymer excipient is currently being evaluated in multiple programs across the globe, enabling delivery of hard-to-formulate APIs from various therapeutic classes and by multiple routes.
Kevin Song, Senior Director, Global Pharmaceutical and Nutraceutical Business, notes "the progression to clinical trials of a medicinal product formulated with Apisolex polymer excipient demonstrates its ability to provide differentiated solutions to solubility and bioavailability challenges in parenteral formulations." Song adds, "Lubrizol continues to invest in expanding the reach of the Apisolex polymer excipient across global markets and nurturing relationships with drug product manufacturers that are facing insoluble API challenges."
Sobre a Lubrizol
A Lubrizol, uma empresa da Berkshire Hathaway, é uma empresa de base científica cuja química especializado oferece sustentável soluções para promover a mobilidade, melhorar o bem-estar e aprimorar a vida moderna. Todos os dias, os inovadores da Lubrizol esforçam-se para criar um valor extraordinário para os clientes no cruzamento entre a ciência, as necessidades do mercado e o sucesso empresarial, impulsionando a descoberta e criando soluções inovadoras que melhoram a vida e fazem o mundo moderno funcionar melhor. Fundada em 1928, a Lubrizol tem alcance global e presença local, com mais de 100 fábricas, escritórios técnicos e de vendas e mais de 7.000 funcionários em todo o mundo. Para mais informações, visite www.Lubrizol.com.
Categorias das Notícias: Health
